Orion Corporation (B)

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

X6002Y112

SEDOL

B17NY40

CIK

N/A

orion.fi

LEI:

FIGI: BBG000BZR2W0

ORNBV

Orion Corporation (B)

GICS: 35202010 · Sector: Health Care · Sub-Sector: Health Care

NAME

Orion Corporation (B)

ISIN

FI0009014377

TICKER

ORNBV

MIC

XHEL

REUTERS

ORNBV.HE

BLOOMBERG

ORNBV FH

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.

Fri, 01.11.2024

ORION CORPORATION
MANAGERS’ TRANSACTIONS
1 NOVEMBER 2024 at 9.45 EET

Research & Analysis

Tue, 29.10.2024

ORION CORPORATION
INTERIM REPORT 1–9/2024
29 OCTOBER 2024 at 12:00 EET

Research & Analysis

Thu, 24.10.2024

ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
24 OCTOBER 2024 at 19.50 EEST

Research & Analysis

Tue, 15.10.2024

ORION CORPORATION
PRESS RELEASE
15 OCTOBER 2024 at 9.00 EEST

Research & Analysis

Mon, 14.10.2024

ORION CORPORATION
INVESTOR NEWS
14 OCTOBER 2024 at 11.00 EEST

Research & Analysis

Mon, 30.09.2024

ORION CORPORATION
PRESS RELEASE
30 SEPTEMBER 2024 at 10.00 a.m. EEST

Research & Analysis

Thu, 26.09.2024

ORION CORPORATION
INVESTOR NEWS
26 SEPTEMBER 2024 at 11.00 EEST

Research & Analysis

Wed, 25.09.2024

ORION CORPORATION
PRESS RELEASE
25 SEPTEMBER 2024 at 15.00 EEST

Research & Analysis

Fri, 20.09.2024

ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
20 SEPTEMBER 2024 at 9.30 EEST

Research & Analysis

Mon, 16.09.2024

ORION CORPORATION
PRESS RELEASE
16 SEPTEMBER 2024 at 11.30 EEST

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Orion Corporation (B)

Orion Corporation: Managers’ transactions – Henrik Stenqvist

Orion Group Interim Report January–September 2024

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

Orion’s near-term climate targets approved by the Science Based Targets initiative

Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

213,285 Orion Corporation A shares converted into B shares

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

Newsletter